*🟢 Obinutuzumab in Active Lupus Nephritis – REGENCY Trial 🏥* #medicalresearch 🔹 Study: Phase 3 RCT evaluating obinutuzumab (anti-CD20 mAb) + standard therapy vs. standard therapy alone in active lupus nephritis. 🔹 Findings (Week 76): • Complete renal response: 46.4% (obinutuzumab) vs. 33.1% (placebo) (P=0.02) • Response with ≤7.5 mg/day prednisone: 42.7% vs. 30.9% (P=0.04) • UPCR <0.8 without events: 55.5% vs. 41.9% (P=0.02) 🔹 Safety: No unexpected signals, but higher serious adverse events (mainly infections, COVID-19-related). 🔹 *Conclusion: Obinutuzumab improves renal outcomes in lupus nephritis when added to standard therapy.* 📖 Source: NEJM, 7 Feb 2025. 🔗 DOI: 10.1056/NEJMoa2400777 @Updates_in_Medicine